Hikma Pharmaceutic (HKMPF) Receives Average Rating of “Hold” from Analysts

Hikma Pharmaceutic (OTCMKTS:HKMPF) has been given an average recommendation of “Hold” by the seven research firms that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has given a buy recommendation to the company.

Several equities analysts have weighed in on HKMPF shares. Zacks Investment Research downgraded Hikma Pharmaceutic from a “hold” rating to a “sell” rating in a research report on Friday, November 10th. ValuEngine raised Hikma Pharmaceutic from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Finally, Jefferies Group downgraded Hikma Pharmaceutic from a “hold” rating to an “underperform” rating in a research report on Wednesday, January 10th.

Hikma Pharmaceutic (OTCMKTS HKMPF) opened at $12.85 on Monday. Hikma Pharmaceutic has a 1 year low of $12.40 and a 1 year high of $27.50.

WARNING: “Hikma Pharmaceutic (HKMPF) Receives Average Rating of “Hold” from Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/12/hikma-pharmaceutic-hkmpf-receives-average-rating-of-hold-from-analysts.html.

Hikma Pharmaceutic Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

Receive News & Ratings for Hikma Pharmaceutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceutic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply